Concepedia
Statistics
Publications
17
Citations
1.6K
H-Index
14
Active since
2001
Affiliations
Novartis (Switzerland)(Current)
The University of Texas MD Anderson Cancer Center
Massachusetts General Hospital
Sarah Cannon
Memorial Sloan Kettering Cancer Center
Douglas Bootle is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and oncology.
Publications per year
2001–2023
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i>-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodón, Josep Tabernero et al. · Journal of Clinical Oncology · 2018 · 439 citations
Medicine, Oncology, Pharmacology +14
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Prakash Mistry, Alistair Stewart, Wendy Dangerfield et al. · PubMed · 2001 · 350 citations
Medicine, Oncology, Pharmacology +16
Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
Dejan Juric, Filip Jankú, Jordi Rodón et al. · JAMA Oncology · 2018 · 260 citations · Full text
Medicine, Oncology, Pharmacology +15
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
M. Campone, Vincent Lévy, Emmanuelle Bourbouloux et al. · British Journal of Cancer · 2009 · 97 citations · Full text
Medicine, Oncology, Pharmacology +17
Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Dejan Juric, Jordi Rodón, Ana M. González-Angulo et al. · Cancer Research · 2012 · 62 citations
1–5 of 17